aflibercept + cisplatin + pemetrexed

Aflibercept + cisplatin + pemetrexed is a combination regimen used in oncology clinical trials, primarily for the treatment of advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).

• Aflibercept (also known as ziv-aflibercept) is a recombinant fusion protein that acts as a decoy receptor for vascular endothelial growth factor (VEGF), thereby inhibiting angiogenesis by preventing VEGF from binding to its native receptors on the surface of endothelial cells.
• Cisplatin is a platinum-based chemotherapeutic agent that forms DNA crosslinks, leading to apoptosis in rapidly dividing cells.
• Pemetrexed is an antifolate antineoplastic agent that inhibits several enzymes involved in folate metabolism and DNA synthesis, including thymidylate synthase and dihydrofolate reductase.

This three-drug combination has been evaluated in phase I and II studies for first-line treatment of patients with previously untreated locally advanced or metastatic non-squamous NSCLC. The regimen typically involves intravenous administration every 21 days, with maintenance aflibercept after initial cycles.